RT Journal Article
T1 Cyclophilins modify their profile depending on the organ or tissue in a murine inflammatory model
A1 Gegunde Mosquera, Sandra
A1 Alfonso Rancaño, María Amparo
A1 Cifuentes Martínez, José Manuel
A1 Alvariño Romero, Rebeca
A1 Pérez Fuentes, Nadia
A1 Rodríguez Vieytes, Mercedes
A1 Botana López, Luis Miguel
K1 Inflammation
K1 Cyclophilins
K1 CD147 receptor
K1 Aorta
K1 Kidney
K1 Liver
K1 Cyclophilin A inhibitor
AB Inflammation is the leading subjacent cause of many chronic diseases. Despite several studies in the last decades, the molecular mechanism involving its pathophysiology is not fully known. Recently, the implication of cyclophilins in inflammatory-based diseases has been demonstrated. However, the main role of cyclophilins in these processes remains elusive. Hence, a mouse model of systemic inflammation was used to better understand the relationship between cyclophilins and their tissue distribution. To induce inflammation, mice were fed with high-fat diet for 10 weeks. In these conditions, serum levels of interleukins 2 and 6, tumour necrosis factor-α, interferon-ϒ, and the monocyte chemoattractant protein 1 were elevated, evidencing a systemic inflammatory state. Then, in this inflammatory model, cyclophilins and CD147 profiles in the aorta, liver, and kidney were studied. The results demonstrate that, upon inflammatory conditions, cyclophilins A and C expression levels were increased in the aorta. Cyclophilins A and D were augmented in the liver, meanwhile, cyclophilins B and C were diminished. In the kidney, cyclophilins B and C levels were elevated. Furthermore, CD147 receptor was also increased in the aorta, liver, and kidney. In addition, when cyclophilin A was modulated, serum levels of inflammatory mediators were decreased, indicating a reduction in systemic inflammation. Besides, the expression levels of cyclophilin A and CD147 were also reduced in the aorta and liver, when cyclophilin A was modulated. Therefore, these results suggest that each cyclophilin has a different profile depending on the tissue, under inflammatory conditions
PB Elsevier
SN 1567-5769
YR 2023
FD 2023-05-24
LK http://hdl.handle.net/10347/31237
UL http://hdl.handle.net/10347/31237
LA eng
NO International Immunopharmacology 120 (2023) 110351
DS Minerva
RD 28 abr 2026